← Back to Search

Tyrosine Kinase Inhibitor

Treatment for Hemangioblastoma

Phase 2

Waitlist Available

Led By Thomas Kaley, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1.5 years

Awards & highlights

All Individual Drugs Already Approved

No Placebo-Only Group

Summary

The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be useful. Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for other tumors. It may be useful in the treatment of brain tumors because it can prevent formation of new blood vessels that allow tumor cells to survive and grow.

Eligible Conditions

Hemangioblastoma
Brain Tumor
Neurofibromatosis
Meningioma
Brain Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Overall Objective Response

Side effects data

From 2019 Phase 2 trial • 305 Patients • NCT01984242

46%

Proteinuria

41%

Fatigue

37%

Arthralgia

30%

Cough

30%

Nausea

28%

Diarrhoea

28%

Epistaxis

26%

Rash

26%

Hypertension

22%

Abdominal pain

22%

Blood creatinine increased

20%

Musculoskeletal pain

20%

Pain in extremity

20%

Constipation

20%

Dysphonia

17%

Oedema peripheral

17%

Pruritus

17%

Upper respiratory tract infection

17%

Back pain

17%

Hypothyroidism

17%

Dyspnoea

15%

Headache

13%

Stomatitis

13%

Vomiting

13%

Mucosal inflammation

13%

Oropharyngeal pain

13%

Pyrexia

11%

Abdominal distension

11%

Hyperglycaemia

11%

Hyponatraemia

11%

Productive cough

11%

Dry mouth

11%

Nasal congestion

11%

Dry skin

Haematuria

Dizziness

Chest pain

Sinusitis

Hypophosphataemia

Hyperkalaemia

Muscle spasms

Night sweats

Decreased appetite

Adrenal insufficiency

Gingival bleeding

Flank pain

Myalgia

Neck pain

Dyspepsia

Blood lactate dehydrogenase increased

Dehydration

Hypoalbuminaemia

Insomnia

Acute kidney injury

Nocturia

Dyspnoea exertional

Rhinorrhoea

Haemorrhoids

Pneumonia

Tumour pain

Rash erythematous

Ecchymosis

Platelet count decreased

Protein total increased

Contusion

Dry eye

Thrombocytopenia

Anaemia

Hypomagnesaemia

Depression

Weight decreased

Pancreatitis acute

Appendicitis

Asthenia

Bronchitis

Muscle haemorrhage

Limb Operation

Embolism

Hypertensive crisis

Oedema

Sepsis

Femur fracture

Paraesthesia

Cardiomyopathy

Urinary tract infection

Diverticulitis

Atrial fibrillation

Anxiety

100%

80%

60%

40%

20%

Study treatment Arm

Atezolizumab (Crossover)

Atezolizumab and Bevacizumab

Atezolizumab

Sunitinib

Sunitinib (Crossover)

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: TreatmentExperimental Treatment1 Intervention

Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Menthol

FDA approved

Do I qualify?Apply below to find out